Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith Wheatley

Showing results (71-80 of 145) with videos related to

Pageof 15
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 14, 2013
Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trialAlan K Burnett, Nigel H Russell, Robert K Hills, et al.
JAMA Neurology|December 28, 2021
Long-term Effectiveness of Adjuvant Treatment With Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared With Dopamine Agonists Among Patients With Parkinson Disease Uncontrolled by Levodopa Therapy: The PD MED Randomized Clinical TrialRichard Gray, Smitaa Patel, Natalie Ives, et al.
Journal of Neuro-Oncology|January 31, 2024
The effectiveness and safety of proton beam radiation therapy in children and young adults with Central Nervous System (CNS) tumours: a systematic reviewJayne S Wilson, Caroline Main, Nicky Thorp, et al.
Journal of Neuro-Oncology|March 5, 2024
Correction to: The effectiveness and safety of proton beam radiation therapy in children and young adults with Central Nervous System (CNS) tumours: a systematic reviewJayne S Wilson, Caroline Main, Nicky Thorp, et al.
British Journal of Haematology|March 18, 2009
The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trialAlan K Burnett, Donald Milligan, Anthony Goldstone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2010
Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trialAlan K Burnett, Robert K Hills, Donald Milligan, et al.
Blood|September 2, 2004
Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapyJames M Allan, Alexandra G Smith, Keith Wheatley, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 6, 2016
Cost-utility analysis of deep brain stimulation surgery plus best medical therapy versus best medical therapy in patients with Parkinson's: Economic evaluation alongside the PD SURG trialEmma McIntosh, Alastair Gray, Jane Daniels, et al.
British Journal of Haematology|February 1, 2006
Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trialsAnupama Rao, Robert K Hills, Charles Stiller, et al.
British Journal of Haematology|April 9, 2005
Del (9q) AML: clinical and cytological characteristics and prognostic implicationsAndrew Peniket, James Wainscoat, Lucy Side, et al.
Pageof 15

Showing results (71-80 of 145) with videos related to

Sort By:
Pageof 15
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 14, 2013
Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trialAlan K Burnett, Nigel H Russell, Robert K Hills, et al.
JAMA Neurology|December 28, 2021
Long-term Effectiveness of Adjuvant Treatment With Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared With Dopamine Agonists Among Patients With Parkinson Disease Uncontrolled by Levodopa Therapy: The PD MED Randomized Clinical TrialRichard Gray, Smitaa Patel, Natalie Ives, et al.
Journal of Neuro-Oncology|January 31, 2024
The effectiveness and safety of proton beam radiation therapy in children and young adults with Central Nervous System (CNS) tumours: a systematic reviewJayne S Wilson, Caroline Main, Nicky Thorp, et al.
Journal of Neuro-Oncology|March 5, 2024
Correction to: The effectiveness and safety of proton beam radiation therapy in children and young adults with Central Nervous System (CNS) tumours: a systematic reviewJayne S Wilson, Caroline Main, Nicky Thorp, et al.
British Journal of Haematology|March 18, 2009
The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trialAlan K Burnett, Donald Milligan, Anthony Goldstone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2010
Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trialAlan K Burnett, Robert K Hills, Donald Milligan, et al.
Blood|September 2, 2004
Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapyJames M Allan, Alexandra G Smith, Keith Wheatley, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 6, 2016
Cost-utility analysis of deep brain stimulation surgery plus best medical therapy versus best medical therapy in patients with Parkinson's: Economic evaluation alongside the PD SURG trialEmma McIntosh, Alastair Gray, Jane Daniels, et al.
British Journal of Haematology|February 1, 2006
Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trialsAnupama Rao, Robert K Hills, Charles Stiller, et al.
British Journal of Haematology|April 9, 2005
Del (9q) AML: clinical and cytological characteristics and prognostic implicationsAndrew Peniket, James Wainscoat, Lucy Side, et al.
Pageof 15